Pharmacological properties and individualized selection of CGRP inhibitors for migraine prevention and acute treatment (PubMed, Zh Nevrol Psikhiatr Im S S Korsakova) - Oct 21, 2026 - "Monoclonal antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab) and small-molecule receptor antagonists (ubrogepant, rimegepant, atogepant) have shown efficacy in episodic and chronic migraine. Study limitations, including short follow-up periods and restricted patient populations, highlight the need for further comparative research in real-world settings. The integration of CGRP inhibitors into migraine management protocols is supported, provided that therapy is tailored to optimize efficacy and safety."
Journal • Review • CNS Disorders • Migraine • Pain
|
|
A M Dogadailova; I I Anisimov; L E Orekhova; M M Batrakhanova; N R Karlov
|